Application notes
Practical Insights for Advancing Gene Delivery
-
Key application notesHydroporator®-Enabled Cell Engineering for Efficient and Cost-Effective CAR-T Cell Therapy
CAR-T cell therapy has demonstrated significant clinical success, particularly in hematologic cancers such as leukemia and lymphoma. While the effectiveness of CAR-T therapy has been well-documented, the use of viral vectors for gene delivery raises serious concerns related to potential mutations, off-targeting, toxicity, and immune responses. Alternatively, mRNA-based CAR-T cell production have been tested under various clinical trials to seek its potential over viral transduction; therefore, we have investigated a new way of manufacturing mRNA-based CAR-T cells via our patented Hydroporator.
Download PDF
-
Application notes
CRISPR Genome Editing of T Cells Using Hydroporator®: Innovating Cell-Based Immunotherapy
Hydroporator, our novel non-viral microfluidic gene delivery platform, enables highly efficient gene editing of the endogenous T cell receptor (TCR) and PD-1 receptor genes, surpassing other traditional approaches in efficiency. These modifications reduce the risk of autoimmune responses by optimizing TCR expression and help prevent T cell exhaustion by knocking out PD-1. Collectively, these genetic changes are designed to enhance T cell functionality, improving the effectiveness of immunotherapies in targeting and eradicating cancer cells.
Download PDF